Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Habermehl, Daniel ^a   Brecht, Ingo C ^a   Bergmann, Frank ^b   Welzel, Thomas ^a   Rieken, Stefan ^a   Werner, Jens ^a   Schirmacher, Peter ^b   Büchler, Markus W ^a   Debus, Jürgen ^a   Combs, Stephanie E ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISTANT METASTASIS; FATIGUE; FEMALE; HUMAN; LAPAROTOMY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PROBABILITY; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 84873021550     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-27     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004, 198:722-731. 10.1016/j.jamcollsurg.2004.01.008, 15110805.
3. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000, 4:567-579. 10.1016/S1091-255X(00)80105-5, 11307091.
4. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2009, 35:600-604. 10.1016/j.ejso.2008.12.006, 19131205.
5. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006, 10:511-518. 10.1016/j.gassur.2005.09.016, 16627216.
6. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997, 226:248-257. discussion 57-60, 10.1097/00000658-199709000-00004, 1191017, 9339931.
7. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825. 10.1056/NEJMoa1011923, 21561347.
8. Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010, 28:4450-4456. 10.1200/JCO.2010.30.3446, 2988636, 20837948.
9. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277. 10.1001/jama.297.3.267, 17227978.
10. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073-1081. 10.1001/jama.2010.1275, 20823433.
11. Habermehl D, Kessel K, Welzel T, et al. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol 2012, 7:28. 10.1186/1748-717X-7-28, 3338091, 22385572.
12. World Health Organization International Agency for Research on Cancer. WHO classification of tumours of the digestive system 2010, Lyon: International Agency for Research on Cancer, 4, World Health Organization.
13. Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008, 15:1651-1660. 10.1245/s10434-008-9839-8, 18351300.
14. Hartwig W, Hackert T, Hinz U, et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg 2009, 250:81-87. 10.1097/SLA.0b013e3181ad657b, 19561478.
15. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004, 91:586-594. 10.1002/bjs.4484, 15122610.
16. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7:e1000267. 10.1371/journal.pmed.1000267, 2857873, 20422030.
17. Wilkowski R, Thoma M, Bruns C, Duhmke E, Heinemann V. Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP 2006, 7:34-40.
18. Strobel O, Hartwig W, Hackert T, et al. Re-resection for Isolated Local Recurrence of Pancreatic Cancer is Feasible, Safe, and Associated with Encouraging Survival. Ann Surg Oncol 2012, Epub ahead of print.
19. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997, 21:195-200. 10.1007/s002689900215, 8995078.
20. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 1993, 72:2118-2123. 10.1002/1097-0142(19931001)72:7<2118::AID-CNCR2820720710>3.0.CO;2-4, 8104092.
21. Ren F, Xu YC, Wang HX, Tang L, Ma Y. Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma: continue or stop?. Pancreatology 2012, 12:162-169.
22. Huang J, Robertson JM, Margolis J, et al. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother Oncol 2011, 99:114-119. 10.1016/j.radonc.2011.05.038, 21621866.
23. Habermehl D, Lindel K, Rieken S, et al. Chemoradiation in patients with unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection: analysis of treatment efficacy and failure in patients receiving postoperative or primary chemoradiation. Strahlenther Onkol 2012, 188:795-801. 10.1007/s00066-012-0099-y, 22526232.
24. Ogawa K, Karasawa K, Ito Y, et al. Intraoperative radiotherapy for unresectable pancreatic cancer: a multi-institutional retrospective analysis of 144 patients. Int J Radiat Oncol Biol Phys 2011, 80:111-118. 10.1016/j.ijrobp.2010.01.065, 20598450.
25. Ogawa K, Karasawa K, Ito Y, et al. Intraoperative radiotherapy for resected pancreatic cancer: a multi-institutional retrospective analysis of 210 patients. Int J Radiat Oncol Biol Phys 2010, 77:734-742. 10.1016/j.ijrobp.2009.09.010, 20207498.